Pages that link to "Q88702827"
Jump to navigation
Jump to search
The following pages link to Andrea Carfì (Q88702827):
Displaying 34 items.
- Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH (Q24297165) (← links)
- Structure-based analysis of the herpes simplex virus glycoprotein D binding site present on herpesvirus entry mediator HveA (HVEM). (Q24538731) (← links)
- The 3-D structure of a zinc metallo-beta-lactamase from Bacillus cereus reveals a new type of protein fold (Q24598128) (← links)
- Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers (Q27667876) (← links)
- Structure of Herpes Simplex Virus Glycoprotein D Bound to the Human Receptor Nectin-1 (Q27674775) (← links)
- Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody (Q27675207) (← links)
- Protein Crystallography in Vaccine Research and Development (Q28087528) (← links)
- Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein (Q28534454) (← links)
- Antigenic Characterization of the HCMV gH/gL/gO and Pentamer Cell Entry Complexes Reveals Binding Sites for Potently Neutralizing Human Antibodies (Q28550400) (← links)
- Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa (Q28552786) (← links)
- Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein (Q28732438) (← links)
- Conformationally selective biophysical assay for influenza vaccine potency determination. (Q30378914) (← links)
- Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41 (Q33523258) (← links)
- Antigenicity-defined conformations of an extremely neutralization-resistant HIV-1 envelope spike (Q33620194) (← links)
- Structural characterization of the fusion-active complex of severe acute respiratory syndrome (SARS) coronavirus. (Q34514760) (← links)
- Structural and biochemical studies of HCMV gH/gL/gO and Pentamer reveal mutually exclusive cell entry complexes (Q35090089) (← links)
- Structure-based mutagenesis of herpes simplex virus glycoprotein D defines three critical regions at the gD-HveA/HVEM binding interface (Q35105049) (← links)
- Targeted entry of enveloped viruses: measles and herpes simplex virus I. (Q35851724) (← links)
- Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody. (Q36084954) (← links)
- Comprehensive Characterization of Reference Standard Lots of HIV-1 Subtype C Gp120 Proteins for Clinical Trials in Southern African Regions (Q37061940) (← links)
- In Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies LJP538 and LJP539. (Q37120061) (← links)
- Potential nectin-1 binding site on herpes simplex virus glycoprotein d. (Q37743232) (← links)
- Expression of the human cytomegalovirus pentamer complex for vaccine use in a CHO system (Q38997531) (← links)
- Structural basis for potent antibody-mediated neutralization of human cytomegalovirus. (Q40092140) (← links)
- Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation (Q40134407) (← links)
- Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase (Q40401488) (← links)
- A monomeric uncleaved respiratory syncytial virus F antigen retains prefusion-specific neutralizing epitopes. (Q41828685) (← links)
- SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness (Q96642646) (← links)
- Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates (Q98157102) (← links)
- SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness (Q98211422) (← links)
- mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants (Q105098698) (← links)
- Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine (Q106105590) (← links)
- mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates (Q108240311) (← links)
- Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates (Q108240357) (← links)